Samsung Bioepis leads in Soliris biosimilar market in Europe

STOCKHOLM – Samsung Bioepis Co.'s biosimilar to Soliris for the treatment of patients with rare, life-threatening disease paroxysmal nocturnal...

Samsung Bioepis releases Soliris biosimilar in Europe

Samsung Bioepis Co., a biopharmaceutical research and development unit under South Korea's Samsung Group, is rolling out its latest product Epysqli,...

Samsung Bioepis to enhance biosimilar presence with Epysqli

FRANKFURT – Samsung Bioepis Co., a biopharmaceutical unit of South Korea’s top conglomerate Samsung, is looking to gain ground in the ra...

Samsung Bioepis gets approval to sell biosimilar in Europe

South Korea's Samsung Bioepis has received approval in Europe to sell a biosimilar of Soliris, a drug for the treatment of adult and children patien...

Samsung Bioepis’ SB12 shows same clinical effects as Alexion’s Soliris

Samsung Bioepis Co., a biopharmaceutical unit of Samsung Group, said its SB12, a proposed biosimilar to Alexion Pharmaceuticals Inc.’s rare bl...